Adverse Effect of Oral Contraceptives, Initial EncounterHORMCONTRANCT01852786
The Effect of Hormonal Contraception on Female
An observational study of Adverse Effect of Oral Contraceptives, Initial Encounter, run by Lithuanian University of Health Sciences at 1 site in Lithuania.
Trial summary
The aim- To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures. Combined oral contraceptives (COCs) is still the most popular contraception method. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Adverse Effect of Oral Contraceptives, Initial Encounter
- What is being tested?
- Contraceptives, Oral, Combined
- Type of treatment
- Pill or oral medicine
- How many people
- 340 participants
- Where
- 1 siteLithuania
- Study dates
- Feb 2013to Feb 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: 340 healthy Lithuanian women age 18- 40 years with regular menstruale cycle (22- 35 days) presenting for routine gynecologic concern or contraception purposes.
Who may be able to join
- 18 - 40 years old women applying to obstetrician-gynaecologist for contraception use or for preventive health care and giving their consent to participate in the study (who signed The Informed Consent Form) will be eligible to participate in the study. It is important to note that these women should not have underlying medical conditions (chronic non - infection diseases, chronic or acute infection diseases).
- Not using hormonal contraception for 6 months or more.
Who cannot join
- Women applying for obstetrician-gynaecologist consultation on gynaecological pathology.
- Women with underlying medical conditions (chronic non - infection diseases, chronic or acute infection diseases).
- Women, planning to get pregnant during the 12 months.
- Pregnant women (suspected or confirmed pregnancy).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Metabolic, Androgen, Blood Coagulation Parameters and Female Sexual Function in Relation to Oral Contraceptive Use and Androgen Receptor Polymorphisms in Healthy Lithuanian Women
The aim- To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures.
Combined oral contraceptives (COCs) is still the most popular contraception method. It is possible to find a number of publications about their non-contraceptive benefits, also about their adverse events. Most researches are conducted during clinical trials, which are commissioned by pharmaceutical companies, in order to compare COCs of different composition. This study set out to assess the role of psychosexual, metabolic, endocrine, hormonal and genetic measures of low dose combined oral contraceptive users- 20 micrograms of Ethinylestradiol/3 mg of Drospirenone and 20 micrograms of Ethinylestradiol/75 micrograms of Gestoden. Because this study is not commercial, it is expected to obtain valuable objective data - there are very few comparative studies about the impact of COCs to woman's organism.
Read the detailed description
The aim
To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures.
The objectives
- To asses the relation of AR polymorphisms to metabolic, androgen, blood coagulation parameters and sexual function in hormonal contraceptive users.
- To compare the changes of metabolic, coagulation and endocrine parameters between hormonal and non-hormonal contraceptive users.
- To assess the impact of COCs on the quality of woman's sexual life and her psychological state.
- To assess the correlation between sex hormones and women's metabolic, endocrine, psychological, sexual function.
- To evaluate the influence of COCs on the blood coagulation parameters.
- To determine the importance of androgen parameters in diagnosis of hyperandrogenism.
Materials and Methods Setting׃ The study will be conducted in Lithuanian University of Health Sciences during the period from 2013 to 2016 years.
4 visits will be proceeded during the study: the screening visit and 3 additional visits - an inclusion in the study visit, a visit after 3 months and a visit after 6 months.
The screening visit (0 visit)
During the screening visit women will be questioned during the routine life and medical history. They will undergo a routine general clinical and gynecological examination:
- height/weight (for BMI calculation) and hip/waist measurements;
- blood pressure (BP) measurement ant a cardiac auscultation (for heart rate (HR) testing);
- auscultation of lungs and palpation of the abdomen;
- assessment of possible veins varicose in the legs;
- bimanual gynecological examination;
- breasts palpation;
- genital ultrasound examination to assess possible anatomical anomalies;
- thyroid ultrasound examination. Women meeting the assessment criteria will be introduced with The Informed Consent Form. Women who signed The Informed Consent Form will be invited to come for the 1 visit.
- visit
Women will repeatedly undergo a routine general examination (BP, HR). Genital and thyroid ultrasound will be performed.
Visual methods to determine the degree of hirsutism, as originally described by Ferriman and Gallwey (F-G), will be performed. The density of terminal hairs at 9 different body sites will be scored from 0 to 4, and total score will be calculated. In addition to the F-G scoring, the height/weight \& hip/waist measurements, will be recorded. Hirsutism will be diagnosed in case of F-G≥8 scores.
- The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
- The women, presenting for non-hormonal contraception use, will be recommended barrier copntraception use(BCM),or Natural family planing methods (NFPM).
Women will be given to fill in six questionnaires׃
- General questionnaire, developed by the authors to find out sociodemographic status;
- Anxiety and Depression Scale (HAD)- to determine the level of anxiety and depression;
- WHO-Five Wellbeing Index (WHO- 5)- to evaluate woman's well being;
- Big Five- to assess personality traits;
- Female Sexual Function Index (FSFI)- to find out the details of their sexual life;
- Dyadic Adjustment Scale (DAD)- to assess the compatibility of the sexual partners.
Following blood tests will be performed׃
- Lipogram, glycemia;
- Hormonal analyses by radioimmunoassay method ׃ total testosterone (T), free testosterone (FT), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAs), thyrotropin hormone (TSH), free thyroxine (FT4);
- Blood coagulation test׃ clotting time according to Ovran, fibrinogen,activated partial thromboplastin time (aPTT).
- Total blood picture test;
- Androgen receptor (AR) polymorphism test. Patients will be invited to come for another visit after 3 months. 2 visit
Women, arriving after 3 months, will be interwied about the changes in well-being and the potential side effects caused by the COCs. Women will undergo a routine general examination BP, HR, height/weight \& hip/waist measurements). Genital and thyroid ultrasound will be performed. The signs of hyperandrogenism will be assessed using F-G scoring system.
Women will be given to fill in six questionnaires׃
- Anxiety and Depression Scale;
- WHO-Five Wellbeing Index;
- Big Five;
- Female Sexual Function Index;
- Dyadic Adjustment Scale;
- Satisfaction Questionnaire- to assess side effects, caused by used contraceptive method.
Patients will be invited to come for another visit after 6 months. 3 visit Women, arriving after 6 months, will be interwied about the changes in well-being and the potential side effects caused by the COCs. Women will undergo a routine general examination BP, HR, height/weight \& hip/waist measurements). The signs of hyperandrogenism will be assessed using F-G scoring system.
Women will be given to fill in six questionnaires׃
- Anxiety and Depression Scale;
- WHO-Five Wellbeing Index;
- Big Five;
- Female Sexual Function Index;
- Dyadic Adjustment Scale;
- Satisfaction Questionnaire. Following blood tests will be performed׃
- Lipogram, glycemia; 2. Hormonal analyses by radioimmunoassay method ׃ T, FT, SHBG, DHEAs, TSH, FT4; 3. Blood coagulation tests׃ clotting time according to Ovran, fibrinogen, aPTT; 4. Total blood picture test.
For further use of COCs patients will consult with the gynecologist performing the study.
- Being tested
- Contraceptives, Oral, Combined, Controls
- Keywords
- Contraception, Hyperandrogenism, Female sexual function
- Medical subject headings
- Hyperandrogenism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Contraceptives, Oral, CombinedOther
Also called COMBINED ORAL CONTRACEPTIVES
- The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
ControlsOther
Also called NATURAL FAMILY PLANNING
The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
| Study group | Role | What they receive |
|---|---|---|
| Contraceptives, Oral, Combined | The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy. Receives: Other: Contraceptives, Oral, Combined | |
| Controls | The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM. Receives: Other: Controls |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hirsutism
The expression of terminal hair growth using Ferriman- Gallwey scoring system in Lithuanian women will be assessed.
Measured: 2 years
Secondary outcomes (4)
Blood coagulation parameters and hormonal contraception
Blood coagulation parameters in six month period will be measured. The risk for development of thromboembolic complications for COCs use will be evaluated.
Measured: 3 years
Lipids concentration
Changes of lipids concentration in COCs users will be identified.
Measured: 3 years
Homeostasis model assessment
Having the results of the glucose concentration in the blood and fasting insulin level tests, the homeostasis model assessment (HOMA) will be calculated and evaluated dynamic changes of this measurement, while using COCs.
Measured: 3 years
Free androgen Index
Having the results of the T and SHBG in the blood Free Androgen Index (FAI) will be calculated. We will compare the effectiveness of diagnostic methods, such as serum free testosterone measured by ELISA-method and free androgen index for assessment of hyperandrogenism in young women with hirsutism.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2013 (estimated)
- Study startFeb 2013
- Primary completionFeb 2015 (estimated)
- Study completionFeb 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adverse Effect of Oral Contraceptives, Initial EncounterStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 340 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lithuanian University of Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lina Ciaplinskiene, Lithuanian University of Health Sciences
- Investigators
- Birute Zilaitiene, Ass. Proff., Principal investigator, Lithuanian University of Health Sciences, Institute of Endocrinology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01852786
- Sponsor's protocol ID
- Contraception
- Other IDs
- contraception2013
- Acronym
- HORMCONTRA
- Status last verified
- May 2013
- First submitted
- 29 Apr 2013
- Last updated
- 14 May 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metabolic, Androgen, Blood Coagulation Parameters and Female Sexual Function in Relation to Oral Contraceptive Use and Androgen Receptor Polymorphisms in Healthy Lithuanian Women
- ClinicalTrials.gov ID
- NCT01852786
- Acronym / sponsor ID
- HORMCONTRA / Contraception
- Keywords
- Contraception, Hyperandrogenism, Female sexual function
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 340 participants (estimated)
- Lead sponsor
- Lithuanian University of Health SciencesUniversity, hospital or other
- Study start
- Feb 2013
- Primary completion
- Feb 2015 (estimated)
- Study completion
- Feb 2016 (estimated)
- First posted
- 14 May 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim- To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures.
Combined oral contraceptives (COCs) is still the most popular contraception method. It is possible to find a number of publications about their non-contraceptive benefits, also about their adverse events. Most researches are conducted during clinical trials, which are commissioned by pharmaceutical companies, in order to compare COCs of different composition. This study set out to assess the role of psychosexual, metabolic, endocrine, hormonal and genetic measures of low dose combined oral contraceptive users- 20 micrograms of Ethinylestradiol/3 mg of Drospirenone and 20 micrograms of Ethinylestradiol/75 micrograms of Gestoden. Because this study is not commercial, it is expected to obtain valuable objective data - there are very few comparative studies about the impact of COCs to woman's organism.
Detailed description
The aim
To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures.
The objectives
- To asses the relation of AR polymorphisms to metabolic, androgen, blood coagulation parameters and sexual function in hormonal contraceptive users.
- To compare the changes of metabolic, coagulation and endocrine parameters between hormonal and non-hormonal contraceptive users.
- To assess the impact of COCs on the quality of woman's sexual life and her psychological state.
- To assess the correlation between sex hormones and women's metabolic, endocrine, psychological, sexual function.
- To evaluate the influence of COCs on the blood coagulation parameters.
- To determine the importance of androgen parameters in diagnosis of hyperandrogenism.
Materials and Methods Setting׃ The study will be conducted in Lithuanian University of Health Sciences during the period from 2013 to 2016 years.
4 visits will be proceeded during the study: the screening visit and 3 additional visits - an inclusion in the study visit, a visit after 3 months and a visit after 6 months.
The screening visit (0 visit)
During the screening visit women will be questioned during the routine life and medical history. They will undergo a routine general clinical and gynecological examination:
- height/weight (for BMI calculation) and hip/waist measurements;
- blood pressure (BP) measurement ant a cardiac auscultation (for heart rate (HR) testing);
- auscultation of lungs and palpation of the abdomen;
- assessment of possible veins varicose in the legs;
- bimanual gynecological examination;
- breasts palpation;
- genital ultrasound examination to assess possible anatomical anomalies;
- thyroid ultrasound examination. Women meeting the assessment criteria will be introduced with The Informed Consent Form. Women who signed The Informed Consent Form will be invited to come for the 1 visit.
- visit
Women will repeatedly undergo a routine general examination (BP, HR). Genital and thyroid ultrasound will be performed.
Visual methods to determine the degree of hirsutism, as originally described by Ferriman and Gallwey (F-G), will be performed. The density of terminal hairs at 9 different body sites will be scored from 0 to 4, and total score will be calculated. In addition to the F-G scoring, the height/weight \& hip/waist measurements, will be recorded. Hirsutism will be diagnosed in case of F-G≥8 scores.
- The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
- The women, presenting for non-hormonal contraception use, will be recommended barrier copntraception use(BCM),or Natural family planing methods (NFPM).
Women will be given to fill in six questionnaires׃
- General questionnaire, developed by the authors to find out sociodemographic status;
- Anxiety and Depression Scale (HAD)- to determine the level of anxiety and depression;
- WHO-Five Wellbeing Index (WHO- 5)- to evaluate woman's well being;
- Big Five- to assess personality traits;
- Female Sexual Function Index (FSFI)- to find out the details of their sexual life;
- Dyadic Adjustment Scale (DAD)- to assess the compatibility of the sexual partners.
Following blood tests will be performed׃
- Lipogram, glycemia;
- Hormonal analyses by radioimmunoassay method ׃ total testosterone (T), free testosterone (FT), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAs), thyrotropin hormone (TSH), free thyroxine (FT4);
- Blood coagulation test׃ clotting time according to Ovran, fibrinogen,activated partial thromboplastin time (aPTT).
- Total blood picture test;
- Androgen receptor (AR) polymorphism test. Patients will be invited to come for another visit after 3 months. 2 visit
Women, arriving after 3 months, will be interwied about the changes in well-being and the potential side effects caused by the COCs. Women will undergo a routine general examination BP, HR, height/weight \& hip/waist measurements). Genital and thyroid ultrasound will be performed. The signs of hyperandrogenism will be assessed using F-G scoring system.
Women will be given to fill in six questionnaires׃
- Anxiety and Depression Scale;
- WHO-Five Wellbeing Index;
- Big Five;
- Female Sexual Function Index;
- Dyadic Adjustment Scale;
- Satisfaction Questionnaire- to assess side effects, caused by used contraceptive method.
Patients will be invited to come for another visit after 6 months. 3 visit Women, arriving after 6 months, will be interwied about the changes in well-being and the potential side effects caused by the COCs. Women will undergo a routine general examination BP, HR, height/weight \& hip/waist measurements). The signs of hyperandrogenism will be assessed using F-G scoring system.
Women will be given to fill in six questionnaires׃
- Anxiety and Depression Scale;
- WHO-Five Wellbeing Index;
- Big Five;
- Female Sexual Function Index;
- Dyadic Adjustment Scale;
- Satisfaction Questionnaire. Following blood tests will be performed׃
- Lipogram, glycemia; 2. Hormonal analyses by radioimmunoassay method ׃ T, FT, SHBG, DHEAs, TSH, FT4; 3. Blood coagulation tests׃ clotting time according to Ovran, fibrinogen, aPTT; 4. Total blood picture test.
For further use of COCs patients will consult with the gynecologist performing the study.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Contraceptives, Oral, Combined | – | Other: Contraceptives, Oral, CombinedThe women, presenting for hormonal contraception use and with no contraindications for hormonal therapy. |
| Controls | – | Other: ControlsThe women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- 340 healthy Lithuanian women age 18- 40 years with regular menstruale cycle (22- 35 days) presenting for routine gynecologic concern or contraception purposes.
Key inclusion criteria (2 listed)
- 18 - 40 years old women applying to obstetrician-gynaecologist for contraception use or for preventive health care and giving their consent to participate in the study (who signed The Informed Consent Form) will be eligible to participate in the study. It is important to note that these women should not have underlying medical conditions (chronic non - infection diseases, chronic or acute infection diseases).
- Not using hormonal contraception for 6 months or more.
Key exclusion criteria (4 listed)
- Women applying for obstetrician-gynaecologist consultation on gynaecological pathology.
- Women with underlying medical conditions (chronic non - infection diseases, chronic or acute infection diseases).
- Women, planning to get pregnant during the 12 months.
- Pregnant women (suspected or confirmed pregnancy).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Contraceptives, Oral, CombinedAlso: COMBINED ORAL CONTRACEPTIVES• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden). | Other | Contraceptives, Oral, Combined |
| ControlsAlso: NATURAL FAMILY PLANNINGThe women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM. | Other | Controls |
Primary outcome
Hirsutism
Time frame: 2 years
The expression of terminal hair growth using Ferriman- Gallwey scoring system in Lithuanian women will be assessed.
4 secondary outcomes
Blood coagulation parameters and hormonal contraception
Time frame: 3 years
Lipids concentration
Time frame: 3 years
Homeostasis model assessment
Time frame: 3 years
Free androgen Index
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2013.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Birute Zilaitiene, Ass. Proff. principal investigator
Lithuanian University of Health Sciences, Institute of Endocrinology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adverse Effect of Oral Contraceptives, Initial Encounter, run by Lithuanian University of Health Sciences at 1 site in Lithuania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 May 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Lithuania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hirsutism (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2013.